Clinical Trial

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-02-16; most recent amendment 2026-06-09.
Status change: Completed → Recruiting 2025-08-05
Status change: Recruiting → Completed 2025-08-04
Status change: Not Yet Recruiting → Recruiting 2024-04-16
Trial Details
NCT Number NCT06276491
Lead Sponsor Xencor, Inc.
Conditions Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Enrollment 282 participants
Start Date 2024-04-04
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-11